EHA 2021 | DREAMM-2: post-hoc analysis of 2.5mg/kg cohort of belantamab mafodotin for myeloma
Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, shares the results of a post-hoc analysis of the Phase II DREAMM-2 study (NCT03525678) at 13 months of follow-up. The DREAMM-2 study is exploring the efficacy and safety of two dose levels of belantamab mafodotin in patients with multiple myeloma who have failed prior treatment with an anti-CD38 antibody. Of 97 patients in the 2.5mg/kg cohort, the clinical benefit rate was 36%. 14 patients experienced at least one ocular event and require two or more dose delays, which permitted recovery and the restarting of treatment. Patients underwent a mean of 3.6 dose delays over 12 or more months of treatment with belantamab mafodotin. Prof. Lonial gives an overview of these findings and comments on the implications for the management of patients receiving belantamab mafodotin. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Transcript (edited for clarity)
So, the DREAMM-2 Study is a randomized Phase II study that led to the FDA and EMA approval of belantamab mafodotin, or belamaf, and this was published, initially, in the Lancet Oncology, and the ultimate dose of belamaf that was agreed to was the 2.5 mgs per kg dose given every three weeks with close partnership of an ophthalmologist.
One of the things that we did in the most recent updated analysis, presented at EHA, was begin to look at patients who had a long response, a median duration of response, of greater than 12 months...
So, the DREAMM-2 Study is a randomized Phase II study that led to the FDA and EMA approval of belantamab mafodotin, or belamaf, and this was published, initially, in the Lancet Oncology, and the ultimate dose of belamaf that was agreed to was the 2.5 mgs per kg dose given every three weeks with close partnership of an ophthalmologist.
One of the things that we did in the most recent updated analysis, presented at EHA, was begin to look at patients who had a long response, a median duration of response, of greater than 12 months. And it was noted that in many of these patients’ dose holds or dose delays were very common. And think the most important thing that we need to teach our colleagues, and our patients, is that the efficacy and activity continued to be very robust, despite the fact that the dose may be held to allow keratopathy to recover.
In fact, many patients who are getting belamaf may get dosed, not on an every three week cycle, but on an every six week cycle, or with alternate, you know, three week then six week, three week, then six week, depending upon the issues with keratopathy. And what we found in this updated analysis was that that approach for patients, actually resulted in better safety, and allowed patients to have very robust durations of response, if they were, in fact, responding. So, very important data on how to manage use and expectations when using belamaf.
Read more...
